American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
August 13, 2026
Earnings Call Speaker Segments
Kirin Smith
executiveAppreciate that, Nick, and I'm glad everyone could join us. Our press release covering AMS' results for the second quarter of 2026 came out earlier today. If you'd like a copy, it's available on the company's website, www.ashs.com, under the Investors section. Ahead of turning things over to management, I'd like to make a few comments regarding forward-looking statements. I'd ask you to note that various things we may say on this conference call concerning the company's future expectations, plans and prospects count as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. There's a chance our actual results could end up quite different from what these forward-looking statements suggest, and that's due to a range of significant factors — among them the ones covered in the documents we file with the SEC, such as our annual report on Form 10-K covering the year that closed on December 31, 2025, along with our Form 10-Q for the quarter that wrapped up on March 31, 2026. We're under no duty to revise anything shared here on this conference call. And before handing things over to management, I want to go over how we handle Q&A: every participant gets a chance to pose one question, plus a follow-up. Naturally, if you have more questions, we're glad to address them after the call. So with all that said, let me pass the call along to Ray Stachowiak, our Executive Chairman. Ray, please go ahead.
Ray Stachowiak
executiveThanks, Kirin, and good afternoon to all of you. We appreciate you being here with us today and for the ongoing interest you've shown in American Shared Hospital Services. Before we get started, I want to take a brief moment to note that we recently gave Alexis Wallace, who has served as our Chief Accounting Officer for a long time, a promotion into the Interim CFO position. Scott Frech, who held the CFO role before her, has departed to follow other pursuits. We send Scott our best wishes and are grateful for what he contributed, and we're happy to welcome Alexis into a role she has certainly earned after so many years of outstanding work on our accounting team. Now, on to the quarter. For our company, the second quarter was yet another stretch of significant operational advancement; we posted robust quarterly revenue of about $8.4 million, which works out to 19% growth compared with the same period last year, and revenue for the first half rose 18%, reaching more than $15.5 million. Continued momentum in our Direct Patient Services business, rising proton beam radiation therapy activity, and better results from our international operations all drove these numbers. Even more significant, in our view, is that these outcomes confirm the strategic path we have been following for the past several years. We have deliberately reshaped American Shared Hospital Services, moving it away from being a business that mainly relied on equipment leasing and toward a more diversified radiation oncology platform offering multiple routes to growth. Today we gain recurring revenues from our direct patient care operations, our long-standing hospital partnerships, international treatment centers, Gamma Knife's leadership, and our participation in proton beam radiation therapy. Every one of these businesses adds to our overall growth strategy in its own way. Taken together, though, they give us an operating platform that is broader and more resilient than it has ever been in our history. A particularly encouraging trend we keep observing is better utilization throughout our network. Patient volumes and operating performance at our Rhode Island centers remain on the rise. Our proton beam radiation therapy partnership in Orlando, Florida turned in another strong quarter, helped by higher treatment volumes and favorable reimbursement trends. On the international side, following the Esprit upgrade we finished in 2025, our Gamma Knife center in Peru continues to show treatment volumes above where they stood a year earlier. These operational wins are particularly heartening because, within our business model, greater utilization stays one of the key drivers of profitability over the long term. I'm also pleased to share that during the first 6 months, our operating activities produced $4.4 million of cash, and our cash balance when the second quarter closed had grown more than 80% from where it was at the start of this year, reaching $6.8 million. Seeing our business generate cash at an improving rate as operating performance keeps getting stronger is a real validation. After the quarter ended, we also made meaningful headway on our capital structure. As a lot of you are aware, we signed a third amendment and forbearance agreement with Fifth Third Bank. Even though our talks around financing have taken up a great deal of management's time across the last several months, we feel this agreement gives us a clear framework that lets us stay focused on carrying out our operating strategy as we keep working toward longer-term capital solutions. Several months back, I set up a new company, and that company just bought additional shares of our company from a private investor. On top of that, this new company put in $2 million of subordinated financing after the quarter ended, which shows our ongoing confidence in the company's long-term prospects and gives us extra financial flexibility going forward. Importantly, none of this financing activity has altered our long-term strategic priorities; in Rhode Island, we keep moving forward on opportunities that came from our certificate of need approvals, such as plans for a new radiation therapy center in Bristol and a proton beam radiation therapy center in Johnston. Abroad, we're still enthusiastic about how our operations in Latin America keep developing and about the chances we see to broaden our footprint in appealing markets. A key piece of our international growth strategy sits in Guadalajara, Mexico, where we're working alongside Hospital San Javier to upgrade their Gamma Knife center. Importantly, this is a proven Gamma Knife market and a highly established clinical partner. Hospital San Javier has delivered Gamma Knife treatments since 1994, which gives us a seasoned physician and institutional platform to build on. While we know there's still significant work in front of us, especially when it comes to our balance sheet, I'm still extremely confident in the fundamental strength of our business. Our attention stays squarely on increasing patient volumes, growing and diversifying our installed base of advanced radiation therapy technologies, reinforcing our partnerships with leading health care systems and directing capital to places where we think it can produce attractive long-term returns. With that, I'll hand the call over to our Interim CEO, Craig Tagawa, who will walk through our operational performance in more detail. Craig?
Craig Tagawa
executiveThanks, Ray, and good afternoon to all of you. I want to add my thanks to each of you for being with us today and for the ongoing interest you've shown in American Shared Hospital Services. Our second quarter delivered yet another period of steady operational performance and significant strides throughout our businesses. Although the financial results we reported contain a number of sizable items that Alexis will walk through in more depth, the key point from this quarter, in my view, is that the business underneath keeps heading in the right direction. We brought in robust quarterly revenues of roughly $8.4 million, which equals 19% growth compared with a year ago, and revenues for the first half climbed past $15.5 million. Those figures came from ongoing expansion in our Direct Patient Services segment, better proton beam radiation therapy results, and greater procedure volumes throughout our international Gamma Knife operations. Even more significant, we keep seeing positive momentum in the measures that matter most to our business's long-term success: patient volumes, utilization, physician engagement, and operating performance at the center level. Starting with Rhode Island, our three radiation oncology centers kept getting better over the quarter. Once again, these facilities produced robust revenue growth, backed by more patient procedures and ongoing operational enhancements. From the time we acquired these centers, our main goal has been to deepen physician relationships, sharpen operational execution, and broaden patient access to high-quality radiation therapy services. We feel we are achieving meaningful progress on all of those goals. Though more opportunities remain in front of us, the direction of these operations is encouraging, and we view them as a key long-term growth platform for the company. Our radiation therapy center in Puebla, Mexico, likewise turned in another strong quarter. Patient activity stayed healthy, reimbursement trends remain favorable, and the operational enhancements we've put in place over the last year are now producing better financial results. Pueblo keeps showing the worth of our international operating strategy, and we think it offers a solid foundation for operational opportunities across Latin America. Now to proton beam radiation therapy. Our leasing arrangement in Orlando produced another outstanding quarter. Revenues rose more than 22% versus a year ago, with both treatment volumes and reimbursement improving. Proton beam radiation therapy continues to be a vital piece of our diversified treatment portfolio, and we're happy with how this asset keeps performing. Our Gamma Knife business likewise kept making encouraging headway. Although domestic leasing volumes still show the effect of one customer agreement expiring last year, we saw robust growth throughout our international Gamma Knife centers. The Esprit upgrade finished in Peru last year keeps generating operational gains via shorter treatment times, better patient throughput, and higher utilization. We think these gains show the worth of continuing to invest in next-generation technology throughout our installed base. Looking across the whole organization, a single theme keeps standing out: utilization. Raising patient throughput remains the biggest single driver of long-term value creation in our business. A great many of our facilities enjoy considerable operating leverage. With procedure volumes still climbing, we anticipate that added revenue will more and more convert into better profitability along with stronger cash generation. That continues to be a key priority for our management team. Outside of what we're running today, we're also enthusiastic about what lies ahead. In Rhode Island, work continues on development possibilities tied to the certificates of need we received approval for previously. Such projects could substantially grow our footprint in one of the markets where we operate best, and they form a key piece of our long-term growth strategy. As Ray said earlier, we also achieved meaningful progress on our financing capabilities following the end of the quarter. Although a great deal of public attention has, quite understandably, been directed at the balance sheet, I think it matters just as much to acknowledge the advances happening across our operating business. Revenue keeps rising, patient volumes keep getting better. Our clinical partners stay strong, and our operating teams keep performing at a very high level. Considered together, these trends bolster our confidence that the business is growing stronger and is better positioned for sustainable long-term growth. There is still work remaining, but I believe the progress we are making today creates the foundation for meaningful long-term value for our shareholders. With that, I'll hand the call over to our Interim Chief Financial Officer, Alexis Wallace, who will walk through our financial results in greater detail. Alexis?
Alexis Wallace
executiveThanks, Craig, and good afternoon to all of you. As Craig pointed out, our second quarter showed ongoing operational momentum throughout the company. We achieved robust expansion in our Direct Patient Services platform, meaningful gains in cash flow from operations, and further advancement in bolstering our liquidity. Although reported earnings took a hit from a number of notable items in the quarter, we think our core operating results kept getting better and offer a strong base for growth ahead. Starting with revenue. Total revenue in the second quarter rose 19.2%, reaching roughly $8.4 million, up from $7.1 million during the same period a year earlier. Across the first 6 months of 2026, revenue grew 17.7% to about $15.5 million, compared with $13.2 million in the first half of 2025. Our Direct Patient Services segment remains the main force behind these results. Revenue for that segment climbed approximately 40% in the second quarter to $4.9 million, and for the first half it was up 35% to roughly $8.9 million; this expansion came mostly from greater patient procedure volumes at our Rhode Island radiation oncology centers, along with yet another robust quarter from our facilities in Peru and Pueblo, Mexico. Notably, these centers keep showing the operating leverage we expected when we invested in them. As patient volumes keep rising, we expect this business to play a steadily larger role in driving both revenue growth and profitability over the long term. In our Medical Equipment Leasing segment, overall revenue was fairly flat versus the prior year. Domestic Gamma Knife leasing activity showed the impact of one customer agreement expiring during 2025, but continued momentum in our proton beam radiation therapy business largely made up for it. Proton beam radiation therapy revenue rose 22% to about $2.3 million in the quarter and roughly $4.3 million across the first 6 months of the year, helped by both increased treatment volumes and better reimbursement rates. Gamma Knife revenue also edged up slightly in the quarter as procedure volumes kept rebounding at our international treatment centers after the Esprit upgrade in Lima was completed. The upgraded platform's greater efficiency has boosted patient throughput and helped drive stronger operating results throughout our international operations. Now on to profitability. Gross margin for the quarter came to about $1.4 million. Though slightly under last year's figure, it rose sequentially from the first quarter of 2026 even as our Direct Patient Services business kept expanding, since that business has a cost structure unlike our traditional equipment leasing operations. We see this as evidence of steady operational execution as we grow that business. Adjusted EBITDA in the second quarter was roughly $1.3 million, versus $1.7 million in the same quarter last year; year-to-date, adjusted EBITDA came to about $2.5 million, which speaks to the ongoing cash-generating strength of our operating platform. Further down the income statement, selling and administrative expenses were higher year-over-year, largely because of legal and professional costs of $285,000 tied to negotiating the third amendment to our credit agreement. On top of that, we took a bigger credit-loss allowance — $909,000 — tied to Rhode Island receivables before May 31, '25. Like we said on earlier calls, our attention has been on upgrading the accounts receivable and billing systems, and that work has moved along nicely, which leaves us in a solid position for what's ahead. Those two things were the main reasons our reported net loss grew this quarter. In our view, neither one has much to do with how the business is actually operating. Strip them out, and the core business keeps performing well, helped by more patients, better reimbursement trends and tight operating discipline. One more positive sign: interest expense kept falling as our average debt balances came down, which shows the work we're doing to shore up the balance sheet. Now to liquidity — we closed the quarter with roughly $6.8 million in cash, cash equivalents and restricted cash, versus $3.7 million at the end of '25. Maybe the best news: operating activities threw off $4.4 million in cash over the first 6 months of the year. That kind of cash generation let us cover scheduled debt repayments and distributions to our minority partners while still growing our cash balance. We think that shows how the business keeps getting better at producing cash as operating performance strengthens. After the quarter closed, we finished the third amendment and forbearance agreement with Fifth Third Bank that we'd announced earlier. That deal gives us more room to maneuver as we keep weighing longer-term financing options and working through our strategic priorities. We also closed a $2 million subordinated financing from a newly formed company set up by our Executive Chairman. Taken together, these moves boost our liquidity, add financial flexibility and let management stay focused on carrying out the operating strategy while chasing chances to further strengthen the capital structure. Going forward, our financial priorities haven't changed. One: keep pushing sustainable revenue growth by lifting utilization across the treatment network we already have while growing our installed base of advanced radiation therapy technologies. Two: turn that revenue growth into better profitability and operating cash flow through disciplined execution and ongoing operating efficiency. And three: keep strengthening the balance sheet and capital structure while holding onto the flexibility we need to back future growth opportunities and create long-term shareholder value. All in all, we're pleased with what we got done in the first half of 2026. The fundamentals underneath our business keep getting better, operating cash flow is still strong, demand across our treatment platform is healthy, and we think the company is set up well to carry this momentum through the rest of the year. With that, Nick, go ahead and open the call for questions.
Marla Marin
analystGiven how strong this quarter was, I recall that when you first started expanding the direct patient operations, you mentioned gaining far more say over procedure volumes and over the capacity to push those volumes higher. From what you've said on earlier conference calls or on this one, it sounds like plenty of opportunities exist for that, especially in Rhode Island, where three centers are located, you have the tie-up with the Brown University health care system, and eventually two additional centers will open. Do you expect the same capacity to steer and boost procedure volume growth at certain international facilities?
Ray Stachowiak
executiveAppreciate that question, Marin. Speaking is Ray Stachowiak, Executive Chairman. Indeed, our volumes at international sites are growing and have been growing. Peru has posted considerable volume gains, particularly after we brought their technology up to the newest and best Esprit model, Gamma Knife. Volume growth has also occurred at our linear accelerator in Puebla, Mexico. Another thing we're eager about is the chance to move ahead with the Gamma Knife upgrade in Guadalajara, Mexico, working alongside San Javier Hospital there, so we're keen to get that project underway and progressing too. And indeed, through possessing more control, negotiating, and broadening our partnerships with hospitals, that has been a central element of our business model.
Tony Kamin
analystTo start, I believe it's quite remarkable that after all the investing and accumulation of various opportunities, the company now appears to be reaping the rewards and hitting its stride, which is genuinely encouraging. I also picked up on the fact that Ray, you, Craig, and Alexis each used the phrase long term, meaning building shareholder value for the company over the long term. As someone who holds shares for the long haul, and I'm certain every long-term shareholder would be thrilled to finally realize the complete benefit of these investments beginning to move in the right direction; that said, I'm struggling to square that with what I found in the third amendment, on Page 31, which states the loan parties shall cause their respective subsidiaries to pursue a sale of all or any portion of all of the assets of ASHS. So, that strikes me as quite explicit as well, that within your agreement, Lake Street is named, bid books are named, meaning you must begin attempting to sell the company. Personally, I would have liked it better if you had managed to swap this loan agreement for one from a different institution, sparing you from that obligation. But once more, the language appears unmistakably clear; so once more, given the desire to seize the long-term opportunity here, how do you accomplish that while simultaneously signing an agreement requiring you to sell all or part of the company?
Ray Stachowiak
executiveWell, I'd say it's accurate that we're exploring every option available; it's quite evident that we received a 12-month extension of the maturity plus — more than 12-month extension of the maturity of our loans to June 30, 2027, so our credit agreement with Fifth Third gives us additional time so that we can explore these various options; we owe Fifth Third roughly $15.5 million by the close of June next year. That figure will drop to approximately $13.3 million. Looking at our business, we produced $4.4 million of cash during the first 6 months of this year; that amount will come directly off our statement of changes in financial position, $4.4 million of cash generation. We finished the quarter holding $6.8 million of cash along with the $2 million deposit we also have. So I believe we'll be able to arrive at a solution during this window to refinance our indebtedness with Fifth Third Bank.
Tony Kamin
analystdoes that mean a sale of the company wouldn't necessarily be needed?
Ray Stachowiak
executiveevery option available is being examined, which is what I'd anticipate our shareholders would want from us. Therefore, all possible paths are being pursued, and we have confidence that a solution will be reached.
Tony Marchese
analystI'm attempting to understand how a charge of nearly $1 million for accounts receivable could happen more than a year afterward. I just don't — what I mean is, does this involve a single account or several? I'm simply attempting to work out what took place. It feels as though each quarter brings something — whether it's a shuttered center, or maintenance, and when it isn't maintenance, now it's accounts receivable. It feels as though the company hits some snag every quarter. So I'm simply attempting to work out, if you could, what the character of the $900,000 accounts receivable charge was, in greater detail, and why identifying it required so much time.
Ray Stachowiak
executiveTony, we really appreciate your remarks. It rather speaks for itself. Through May 31, 2025, we held receivables tied to a number of payers and to our connections with those payers; and eventually we arrived at a point where we anticipate a $909,000 decline in how collectible those receivables are.
Tony Marchese
analystRay, I want to avoid coming across as obstinate here. What exactly does that signify, though? Have the payers gone insolvent? Is it that they're unwilling to remit payment to you? Did something go wrong with the — I'm merely attempting to determine, since this figure is rather substantial. So I'm just attempting to determine whether these payers — when you refer to them as payers, does that mean insurance firms? Does it mean clients? Or does it mean individuals who received treatment and afterward were unable to cover the cost? Or I'm just attempting to determine what kind of charge this actually is.
Ray Stachowiak
executiveYes. In the main, it stems from the insurance carriers with whom we maintain relationships.
Tony Marchese
analystWas there some main reason behind their refusal to compensate you? I mean, these are insurers. In my view, they're pretty sophisticated organizations, and they wouldn't simply refuse payment without cause. So I'm curious whether the problem was that the work wasn't carried out correctly, or if something was wrong with the service itself? I'm not attempting to make things hard, Ray. I'm only asking — could this occur again? And if so, what would cause it?
Ray Stachowiak
executiveIt's not something we feel good about, Tony. It's not something we feel good about, but it is what it is.
Tony Marchese
analystCertainly not.
Craig Tagawa
executiveNick, I appreciate that, and my thanks go out to each of you who took part in today's call. As we wrap up, I want to share three main points that stand out from what we discussed. To begin with, things are still going strongly in our operating business. Revenue for the quarter came in robust, patient volumes kept climbing across several treatment platforms, and we produced solid cash flow from operations through the first half of the year. Next, the strategic investments made during the last several years are now delivering tangible outcomes. Growth continues in our Direct Patient Services business, momentum is building in our international operations, and we have an exciting pipeline of future expansion opportunities that we believe will underpin long-term value creation. Last, though our attention stays on reinforcing the balance sheet, we have taken significant steps to boost our financial flexibility and we remain dedicated to carrying out our long-term strategy with discipline and transparency. My gratitude goes to our physicians, clinical teams, employees, hospital partners and shareholders for the confidence and support you keep showing us. We value your interest in America Shared Hospital Services and we look forward to bringing you an update on our continued progress next quarter. Thanks to all of you, and enjoy a wonderful evening.
Operator
operatorThat brings today's presentation to a close. We appreciate your participation in this session. You're welcome to leave the call at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.